Recent submissions

  • Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues. 

    Khan, AA; Paget, JT; McLaughlin, M; Kyula, JN; Wilkinson, MJ; Pencavel, T; Mansfield, D; Roulstone, V; Seth, R; Halle, M; Somaiah, N; Boult, JKR; Robinson, SP; Pandha, HS; Vile, RG; Melcher, AA; Harris, PA; Harrington, KJ (2018-01-24)
    Improvements in cancer survival mean that long-term toxicities, which contribute to the morbidity of cancer survivorship, are being increasingly recognized. Late adverse effects (LAEs) in normal tissues after radiotherapy ...
  • Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapy. 

    Dean, J; Wong, K; Gay, H; Welsh, L; Jones, A-B; Schick, U; Oh, JH; Apte, A; Newbold, K; Bhide, S; Harrington, K; Deasy, J; Nutting, C; Gulliford, S (2018-01)
    Severe acute dysphagia commonly results from head and neck radiotherapy (RT). A model enabling prediction of severity of acute dysphagia for individual patients could guide clinical decision-making. Statistical associations ...
  • Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. 

    Samson, A; Scott, KJ; Taggart, D; West, EJ; Wilson, E; Nuovo, GJ; Thomson, S; Corns, R; Mathew, RK; Fuller, MJ; Kottke, TJ; Thompson, JM; Ilett, EJ; Cockle, JV; van Hille, P; Sivakumar, G; Polson, ES; Turnbull, SJ; Appleton, ES; Migneco, G; Rose, AS; Coffey, MC; Beirne, DA; Collinson, FJ; Ralph, C; Alan Anthoney, D; Twelves, CJ; Furness, AJ; Quezada, SA; Wurdak, H; Errington-Mais, F; Pandha, H; Harrington, KJ; Selby, PJ; Vile, RG; Griffin, SD; Stead, LF; Short, SC; Melcher, AA (2018-01-03)
    Immune checkpoint inhibitors, including those targeting programmed cell death protein 1 (PD-1), are reshaping cancer therapeutic strategies. Evidence suggests, however, that tumor response and patient survival are determined ...
  • HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. 

    Martins, CD; Da Pieve, C; Burley, TA; Smith, R; Ciobota, DM; Allott, L; Harrington, KJ; Oyen, WJG; Smith, G; Kramer-Marek, G (2018-02-06)
    Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). ...
  • Radiotherapy in Dupuytren's disease: a systematic review of the evidence 

    Kadhum, M; Smock, E; Khan, A; Fleming, A (2017-09)
  • PET/CT with 89Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion 

    Hekman, MCH; Rijpkema, M; Aarntzen, EA; Mulder, SF; Langenhuijsen, JF; Oosterwijk, E; Boerman, OC; Oyen, WJG; Mulders, PFA
    Based on the high expression of Carbonic Anhydrase IX (CAIX) in 95% of clear cell renal cell carcinoma (ccRCC), the anti-CAIX monoclonal antibody girentuximab can be used for the detection of ccRCC. This clinical study ...
  • Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 

    Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; de Bono, JS; Attard, G; Chowdhury, S; Cross, B; Gillessen, S; Malik, Z; Jones, R; Parker, C; Ritchie, AWS; Russell, JM; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, D; Hughes, R; McLaren, D; Lester, J; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, SM; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, MKB; James, ND (2018-02-26)
    Background: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in STAMPEDE: a multi-arm multi-stage platform randomised controlled ...
  • Men with a susceptibility to prostate cancer and the role of genetic based screening. 

    Eeles, R; Ni Raghallaigh, H (2018-02)
    Prostate cancer is the second most common malignancy affecting men worldwide, and the commonest affecting men of African descent. Significant diagnostic and therapeutic advances have been made in the past decade. Improvements ...
  • Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. 

    Conti, DV; Wang, K; Sheng, X; Bensen, JT; Hazelett, DJ; Cook, MB; Ingles, SA; Kittles, RA; Strom, SS; Rybicki, BA; Nemesure, B; Isaacs, WB; Stanford, JL; Zheng, W; Sanderson, M; John, EM; Park, JY; Xu, J; Stevens, VL; Berndt, SI; Huff, CD; Wang, Z; Yeboah, ED; Tettey, Y; Biritwum, RB; Adjei, AA; Tay, E; Truelove, A; Niwa, S; Sellers, TA; Yamoah, K; Murphy, AB; Crawford, DC; Gapstur, SM; Bush, WS; Aldrich, MC; Cussenot, O; Petrovics, G; Cullen, J; Neslund-Dudas, C; Stern, MC; Jarai, Z-K; Govindasami, K; Chokkalingam, AP; Hsing, AW; Goodman, PJ; Hoffmann, T; Drake, BF; Hu, JJ; Clark, PE; Van Den Eeden, SK; Blanchet, P; Fowke, JH; Casey, G; Hennis, AJM; Han, Y; Lubwama, A; Thompson, IM; Leach, R; Easton, DF; Schumacher, F; Van den Berg, DJ; Gundell, SM; Stram, A; Wan, P; Xia, L; Pooler, LC; Mohler, JL; Fontham, ETH; Smith, GJ; Taylor, JA; Srivastava, S; Eeles, RA; Carpten, J; Kibel, AS; Multigner, L; Parent, M-E; Menegaux, F; Cancel-Tassin, G; Klein, EA; Brureau, L; Stram, DO; Watya, S; Chanock, SJ; Witte, JS; Blot, WJ; Henderson, BE; Haiman, CA; PRACTICAL/ELLIPSE Consortium (2017-08-01)
    Prostate cancer incidence is 1.6-fold higher in African Americans than in other populations. The risk factors that drive this disparity are unknown and potentially consist of social, environmental, and genetic influences. ...
  • Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. 

    Girardi, F; Barnes, DR; Barrowdale, D; Frost, D; Brady, AF; Miller, C; Henderson, A; Donaldson, A; Murray, A; Brewer, C; Pottinger, C; Evans, DG; Eccles, D; EMBRACE; Lalloo, F; Gregory, H; Cook, J; Eason, J; Adlard, J; Barwell, J; Ong, KR; Walker, L; Izatt, L; Side, LE; Kennedy, MJ; Tischkowitz, M; Rogers, MT; Porteous, ME; Morrison, PJ; Eeles, R; Davidson, R; Snape, K; Easton, DF; Antoniou, AC (2018-03-22)
    PurposeBRCA1/BRCA2 predictive test negatives are proven noncarriers of a BRCA1/BRCA2 mutation that is carried by their relatives. The risk of developing breast cancer (BC) or epithelial ovarian cancer (EOC) in these women ...
  • Intensity modulated radiotherapy in locally advanced thyroid cancer: Outcomes of a sequential phase I dose-escalation study. 

    Rooney, KP; Miah, AB; Bhide, SA; Guerrero-Urbano, MT; Sharabiani, MT; Newbold, KL; Grove, L; Harrington, KJ; Nutting, CM (2018-03-07)
    BACKGROUND AND PURPOSE: To determine the safety and tolerability of dose-escalation using modestly accelerated IMRT in high-risk locally advanced thyroid cancer requiring post-operative radiotherapy, and to report preliminary ...
  • Comparison of six fit algorithms for the intra-voxel incoherent motion model of diffusion-weighted magnetic resonance imaging data of pancreatic cancer patients 

    Gurney-Champion, O; Klaassen, R; Froeling, M; Barbieri, S; Stoker, J; Engelbrecht, MRW; Wilmink, JW; Besselink, MG; van Laarhoven, HWM; Nederveen, AJ
  • Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. 

    Wilkins, AC; Gusterson, B; Szijgyarto, Z; Haviland, J; Griffin, C; Stuttle, C; Daley, F; Corbishley, CM; Dearnaley, DP; Hall, E; Somaiah, N; CHHiP Trial Investigators (2018-02-03)
    PURPOSE: To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a ...
  • Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. 

    Vijayakrishnan, J; Studd, J; Broderick, P; Kinnersley, B; Holroyd, A; Law, PJ; Kumar, R; Allan, JM; Harrison, CJ; Moorman, AV; Vora, A; Roman, E; Rachakonda, S; Kinsey, SE; Sheridan, E; Thompson, PD; Irving, JA; Koehler, R; Hoffmann, P; Nöthen, MM; Heilmann-Heimbach, S; Jöckel, K-H; Easton, DF; Pharaoh, PDP; Dunning, AM; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; Greaves, M; Zimmerman, M; Bartram, CR; Schrappe, M; Stanulla, M; Hemminki, K; Houlston, RS; PRACTICAL Consortium (2018-04-09)
    Genome-wide association studies (GWAS) have advanced our understanding of susceptibility to B-cell precursor acute lymphoblastic leukemia (BCP-ALL); however, much of the heritable risk remains unidentified. Here, we perform ...
  • Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene. 

    Litchfield, K; Loveday, C; Levy, M; Dudakia, D; Rapley, E; Nsengimana, J; Bishop, DT; Reid, A; Huddart, R; Broderick, P; Houlston, RS; Turnbull, C (2018-02-09)
    Testicular germ cell tumour (TGCT), the most common cancer in young men, has a significant heritable basis that has long raised questions as to the existence of underlying major high-penetrance susceptibility gene(s). To ...
  • Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer. 

    Loveday, C; Litchfield, K; Levy, M; Holroyd, A; Broderick, P; Kote-Jarai, Z; Dunning, AM; Muir, K; Peto, J; Eeles, R; Easton, DF; Dudakia, D; Orr, N; Pashayan, N; Reid, A; Huddart, RA; Houlston, RS; Turnbull, C (2018-02-27)
    Testicular germ cell tumor (TGCT), the most common cancer in men aged 18 to 45 years, has a strong heritable basis. Genome-wide association studies (GWAS) have proposed single nucleotide polymorphisms (SNPs) at a number ...
  • Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. 

    Mikropoulos, C; Hutten Selkirk, CG; Saya, S; Bancroft, E; Vertosick, E; Dadaev, T; Brendler, C; Page, E; Dias, A; Evans, DG; Rothwell, J; Maehle, L; Axcrona, K; Richardson, K; Eccles, D; Jensen, T; Osther, PJ; van Asperen, CJ; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Hart, R; Glover, W; Lam, J; Taylor, L; Salinas, M; Feliubadaló, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Cook, J; Rosario, DJ; Buys, SS; Conner, T; Domchek, S; Powers, J; Ausems, MGEM; Teixeira, MR; Maia, S; Izatt, L; Schmutzler, R; Rhiem, K; Foulkes, WD; Boshari, T; Davidson, R; Ruijs, M; Helderman-van den Enden, ATJM; Andrews, L; Walker, L; Snape, K; Henderson, A; Jobson, I; Lindeman, GJ; Liljegren, A; Harris, M; Adank, MA; Kirk, J; Taylor, A; Susman, R; Chen-Shtoyerman, R; Pachter, N; Spigelman, A; Side, L; Zgajnar, J; Mora, J; Brewer, C; Gadea, N; Brady, AF; Gallagher, D; van Os, T; Donaldson, A; Stefansdottir, V; Barwell, J; James, PA; Murphy, D; Friedman, E; Nicolai, N; Greenhalgh, L; Obeid, E; Murthy, V; Copakova, L; McGrath, J; Teo, S-H; Strom, S; Kast, K; Leongamornlert, DA; Chamberlain, A; Pope, J; Newlin, AC; Aaronson, N; Ardern-Jones, A; Bangma, C; Castro, E; Dearnaley, D; Eyfjord, J; Falconer, A; Foster, CS; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Lubinski, J; Grindedal, EM; McKinley, J; Shackleton, K; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Tricker, K; IMPACT study collaborators; Moss, S; Kote-Jarai, Z; Vickers, A; Lilja, H; Helfand, BT; Eeles, RA (2018-03-20)
    This corrects the article DOI: 10.1038/bjc.2017.429.
  • The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model. 

    Papaevangelou, E; Almeida, GS; Box, C; deSouza, NM; Chung, Y-L (2018-03-23)
    Overexpression of fatty acid synthase (FASN), a key regulator of the de novo synthesis of fatty acids, has been demonstrated in a variety of cancers and is associated with poor prognosis and increased multidrug resistance. ...
  • Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models. 

    Wong Te Fong, A-C; Thavasu, P; Gagrica, S; Swales, KE; Leach, MO; Cosulich, SC; Chung, Y-L; Banerji, U (2017-12-26)
    Activation of the PI3K/mTOR pathway has been shown to be correlated with resistance to chemotherapy in ovarian cancer. We aimed to investigate the effects of combining inhibition of mTORC1 and 2 using the mTOR kinase ...

View more